Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company whose news flow centers on its TGF-ß pathway–focused pipeline, corporate strategy and capital allocation decisions. The company’s disclosures describe a focus on developing protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, with particular emphasis on neuromuscular and hematologic conditions.
News about Keros frequently highlights clinical development milestones for its lead product candidate, KER-065, which is being developed for neuromuscular diseases with an initial focus on Duchenne muscular dystrophy. Recent updates have included Phase 1 clinical data in healthy volunteers, additional analyses of bone and muscle-related endpoints, and U.S. Food and Drug Administration Orphan Drug designation for KER-065 in DMD. Investors following KROS news can expect coverage of trial design, safety and pharmacodynamic findings, and plans for subsequent clinical phases.
Another recurring theme in Keros news is progress related to elritercept, the company’s most advanced product candidate for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. The company has reported developments under its global license agreement with Takeda Pharmaceuticals U.S.A., Inc., including Takeda’s plans to advance elritercept into a Phase 3 clinical trial in first-line myelodysplastic syndromes.
Keros’ news flow also includes corporate and financial updates. These have covered a strategic realignment to prioritize KER-065, discontinuation of internal development of cibotercept (KER-012), leadership and board changes, and a substantial capital return program involving stock repurchase agreements and a cash tender offer for a significant portion of its outstanding common stock. Earnings releases and Form 8-K filings provide additional context on financial results, cash position and the execution of the capital return plan.
For investors and observers, the KROS news page offers a consolidated view of clinical trial announcements, regulatory designations, partnership developments, governance changes and capital allocation actions that shape the company’s trajectory. Regular review of these updates can help track how Keros advances its TGF-ß–focused pipeline and manages its resources over time.
Keros Therapeutics (Nasdaq: KROS) entered an agreement on March 9, 2026, with Massachusetts General Hospital to design a Phase 2 clinical trial evaluating rinvatercept in ALS patients under the Healey ALS MyMatch program.
The collaboration will use biomarker-driven, personalized trial methods to match ALS subgroups to experimental therapies and to identify optimal populations for later-stage trials.
Keros Therapeutics (Nasdaq: KROS) presented additional Phase 1 clinical data for rinvatercept (KER-065) at the 2026 MDA Clinical & Scientific Conference on March 9, 2026. Findings in healthy volunteers showed tolerability, body composition changes, and proteomic evidence of target engagement guiding development for DMD and ALS.
Key takeaways: generally well-tolerated with no dose-limiting toxicities or serious adverse events; increases in muscle mass and bone mineral density; decreases in fat mass; proteomic signals consistent with activin/myostatin inhibition, anti-fibrotic and anti-inflammatory effects.
Keros (Nasdaq: KROS) reported fourth-quarter 2025 net loss of $23.5M and full-year 2025 net income of $87.0M, driven largely by revenue from a license agreement with Takeda. The company expects to start a Phase 2 trial of rinvatercept in DMD in Q2 2026 and to engage regulators on an ALS Phase 2 design in H2 2026. Cash and cash equivalents were $287.4M at year-end, with management saying this funding is expected to support operations into the first half of 2028.
Keros Therapeutics (Nasdaq: KROS) appointed Charles Newton to its Board of Directors, effective March 9, 2026, and announced that Carl Gordon, Ph.D., CFA, will step down as director effective the same date.
Mr. Newton joins with healthcare finance and capital markets experience, including service as CFO of Lyell through September 2025 and current board roles at Novavax and Coherus Oncology.
Keros Therapeutics (Nasdaq: KROS) announced that CEO Jasbir S. Seehra, Ph.D., will present at three healthcare conferences in late February and March 2026: Oppenheimer (Feb 25), TD Cowen (Mar 3) and Leerink Partners (Mar 10).
Each presentation format is listed (corporate presentation or fireside chat) and archived replays will be available on the company investor website for up to 90 days after each event.
Keros Therapeutics (Nasdaq: KROS) announced final results of its cash tender offer to repurchase up to 10,950,165 shares at $17.75 per share for an aggregate purchase price of approximately $194.4 million. The Tender Offer expired on November 18, 2025 and concludes the company’s previously announced $375 million capital return program.
Computershare reported 17,712,262 shares were validly tendered; Keros accepted 10,950,165 shares on a pro rata basis with a final proration factor of approximately 62.30%. The purchased shares represent about 35.91% of outstanding common stock as of November 18, 2025. Payment for accepted shares will be made promptly from the company’s cash and cash equivalents.
Keros Therapeutics (Nasdaq: KROS) announced preliminary results of a cash tender offer that expired on November 18, 2025 to repurchase up to 10,950,165 shares at $17.75 per share for an aggregate purchase price of approximately $194.4 million. The tender concludes the company’s $375 million capital return program.
Approximately 16,659,732 shares were validly tendered (plus 1,186,829 via guaranteed delivery). Keros expects to accept 10,950,165 shares on a pro rata basis, representing about 35.91% of outstanding common stock as of November 18, 2025. Final counts are subject to Depositary confirmation.
Keros Therapeutics (Nasdaq: KROS) reported third quarter 2025 results on November 5, 2025. The company posted a net loss of $7.3 million in Q3 2025 versus a net loss of $53.0 million in Q3 2024, driven largely by revenue recognized under its license agreement with Takeda and a shift of elritercept R&D costs to Takeda.
R&D expenses were $19.5 million in Q3 2025 versus $49.2 million a year earlier. G&A expenses were $10.1 million versus $9.8 million. Cash and cash equivalents totaled $693.5 million as of September 30, 2025. The board has determined to return $375.0 million of excess capital to stockholders; after that amount, management expects cash to fund operations into the first half of 2028. Takeda plans to advance elritercept into a Phase 3 first-line MDS trial, and Keros plans to initiate a Phase 2 trial of KER-065 in Duchenne muscular dystrophy.
Keros Therapeutics (Nasdaq: KROS) commenced a cash tender offer on Oct 20, 2025 to repurchase up to $194.4 million of its common stock at $17.75 per share, part of a previously announced $375 million capital return program. The company expects to fund the tender offer from existing cash and cash equivalents.
The offer is scheduled to expire at 5:00 p.m. ET on Nov 18, 2025, unless extended or terminated. The company and its board made no recommendation to shareholders; full terms are filed with the SEC.
Keros Therapeutics (Nasdaq: KROS) announced agreements to repurchase all shares held by ADAR1 Capital Management and Pontifax at $17.75 per share, for an aggregate purchase price of approximately $181 million, expected to close on October 15, 2025.
As part of a previously announced $375 million capital return program, Keros intends to commence a tender offer by the end of October 2025 to repurchase up to $194 million of additional shares at $17.75 per share, funded from existing cash and cash equivalents.
The company also plans to distribute 25% of any net cash proceeds received on or before December 31, 2028 from its global license agreement with Takeda to stockholders. Two directors, Ran Nussbaum and Tomer Kariv, resigned effective immediately.